Cellectis (NASDAQ:CLLS) Rating Increased to Strong-Buy at Barclays

Cellectis (NASDAQ:CLLS) was upgraded by equities researchers at Barclays to a “strong-buy” rating in a research report issued to clients and investors on Thursday,Zacks.com reports.

A number of other research analysts have also recently issued reports on CLLS. Weiss Ratings reissued a “sell (d-)” rating on shares of Cellectis in a report on Monday, April 20th. Jefferies Financial Group assumed coverage on shares of Cellectis in a research report on Tuesday, February 17th. They set a “buy” rating and a $7.00 target price for the company. Finally, Citizens Jmp reissued a “market outperform” rating and set a $8.00 price target on shares of Cellectis in a report on Tuesday, April 14th. Two research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $7.00.

Cellectis Stock Performance

Shares of CLLS opened at $3.63 on Thursday. The company has a current ratio of 1.52, a quick ratio of 1.52 and a debt-to-equity ratio of 1.13. The stock has a market cap of $364.23 million, a PE ratio of -5.42 and a beta of 2.94. Cellectis has a 1 year low of $1.33 and a 1 year high of $5.48. The stock has a 50 day simple moving average of $3.70 and a 200-day simple moving average of $4.03.

Cellectis (NASDAQ:CLLS) last announced its quarterly earnings results on Monday, May 11th. The biotechnology company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.08. Cellectis had a negative return on equity of 80.66% and a negative net margin of 89.51%.The business had revenue of $7.55 million for the quarter, compared to analyst estimates of $11.04 million.

Hedge Funds Weigh In On Cellectis

A number of institutional investors and hedge funds have recently bought and sold shares of CLLS. Lido Advisors LLC bought a new stake in shares of Cellectis during the first quarter worth $32,000. Marshall Wace LLP raised its holdings in shares of Cellectis by 1,610.3% in the fourth quarter. Marshall Wace LLP now owns 178,473 shares of the biotechnology company’s stock valued at $864,000 after buying an additional 168,038 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in Cellectis during the 4th quarter worth about $15,385,000. Global Retirement Partners LLC acquired a new position in Cellectis during the 4th quarter worth about $34,000. Finally, Millennium Management LLC grew its holdings in Cellectis by 61.9% during the 3rd quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company’s stock worth $165,000 after acquiring an additional 22,080 shares during the last quarter. Institutional investors and hedge funds own 63.90% of the company’s stock.

Cellectis Company Profile

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.